PH12018502327A1 - Phenolic compound and combination thereof with a benzodiazepin melted to 1,4-dihydropyridine for the treatment of central and vascular nervous system affections - Google Patents
Phenolic compound and combination thereof with a benzodiazepin melted to 1,4-dihydropyridine for the treatment of central and vascular nervous system affectionsInfo
- Publication number
- PH12018502327A1 PH12018502327A1 PH12018502327A PH12018502327A PH12018502327A1 PH 12018502327 A1 PH12018502327 A1 PH 12018502327A1 PH 12018502327 A PH12018502327 A PH 12018502327A PH 12018502327 A PH12018502327 A PH 12018502327A PH 12018502327 A1 PH12018502327 A1 PH 12018502327A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- affections
- benzodiazepin
- dihydropyridine
- melted
- Prior art date
Links
- 150000002989 phenols Chemical class 0.000 title abstract 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002792 vascular Effects 0.000 title abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- -1 polyphenol compounds Chemical class 0.000 abstract 2
- 235000013824 polyphenols Nutrition 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 230000001910 anti-glutamatergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003371 gabaergic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000059A CU24576B1 (es) | 2016-05-04 | 2016-05-04 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
| PCT/CU2017/050003 WO2017190714A1 (es) | 2016-05-04 | 2017-05-03 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018502327A1 true PH12018502327A1 (en) | 2019-09-02 |
Family
ID=60202803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018502327A PH12018502327A1 (en) | 2016-05-04 | 2018-11-05 | Phenolic compound and combination thereof with a benzodiazepin melted to 1,4-dihydropyridine for the treatment of central and vascular nervous system affections |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10722491B2 (enExample) |
| EP (1) | EP3453704B1 (enExample) |
| JP (1) | JP6997995B2 (enExample) |
| KR (1) | KR102416478B1 (enExample) |
| CN (1) | CN109476627B (enExample) |
| AR (1) | AR108370A1 (enExample) |
| AU (1) | AU2017259749C1 (enExample) |
| BR (1) | BR112018072579B1 (enExample) |
| CA (1) | CA3023073C (enExample) |
| CL (1) | CL2018003114A1 (enExample) |
| CO (1) | CO2018011927A2 (enExample) |
| CU (1) | CU24576B1 (enExample) |
| EA (1) | EA037951B1 (enExample) |
| ES (1) | ES2878579T3 (enExample) |
| MX (1) | MX384967B (enExample) |
| PH (1) | PH12018502327A1 (enExample) |
| SG (1) | SG11201809843SA (enExample) |
| WO (1) | WO2017190714A1 (enExample) |
| ZA (1) | ZA201808161B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20160058A7 (es) | 2016-05-04 | 2017-12-08 | Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular |
| WO2020077406A1 (en) * | 2018-10-16 | 2020-04-23 | Saban Ventures Pty Limited | Apparatus and method for cleaning a medical device |
| WO2021139842A2 (es) * | 2019-12-26 | 2021-07-15 | Centro de Investigación Y Desarrollo de Medicamentos CIDEM | Uso de un derivado benzodiacepínico y método de tratamiento del trauma craneoencefálico |
| CU20190114A7 (es) | 2019-12-26 | 2021-08-06 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281714A (en) | 1990-08-16 | 1994-01-25 | American Home Products Corporation | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase |
| MX9204939A (es) | 1991-09-06 | 1993-03-01 | American Home Prod | Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa. |
| EP0578849B1 (en) | 1992-07-17 | 1995-05-17 | Biogal Gyogyszergyar | Process for the preparation of 1,3-dioxane-4,6-dione derivates |
| JPH11180975A (ja) | 1997-10-13 | 1999-07-06 | Chemiprokasei Kaisha Ltd | アミノメチレンジオキサン誘導体、その製造方法および用途 |
| EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| JP2007063444A (ja) * | 2005-08-31 | 2007-03-15 | Tdk Corp | 錯化合物及びこれを用いた光記録媒体 |
-
2016
- 2016-05-04 CU CU2016000059A patent/CU24576B1/es unknown
-
2017
- 2017-05-03 BR BR112018072579-0A patent/BR112018072579B1/pt not_active IP Right Cessation
- 2017-05-03 CA CA3023073A patent/CA3023073C/en active Active
- 2017-05-03 WO PCT/CU2017/050003 patent/WO2017190714A1/es not_active Ceased
- 2017-05-03 EP EP17732730.1A patent/EP3453704B1/en active Active
- 2017-05-03 JP JP2019510749A patent/JP6997995B2/ja not_active Expired - Fee Related
- 2017-05-03 AU AU2017259749A patent/AU2017259749C1/en not_active Ceased
- 2017-05-03 MX MX2018013422A patent/MX384967B/es unknown
- 2017-05-03 US US16/098,683 patent/US10722491B2/en not_active Expired - Fee Related
- 2017-05-03 EA EA201892462A patent/EA037951B1/ru unknown
- 2017-05-03 ES ES17732730T patent/ES2878579T3/es active Active
- 2017-05-03 SG SG11201809843SA patent/SG11201809843SA/en unknown
- 2017-05-03 KR KR1020187035042A patent/KR102416478B1/ko not_active Expired - Fee Related
- 2017-05-03 CN CN201780040492.9A patent/CN109476627B/zh not_active Expired - Fee Related
- 2017-05-04 AR ARP170101153A patent/AR108370A1/es unknown
-
2018
- 2018-10-31 CL CL2018003114A patent/CL2018003114A1/es unknown
- 2018-11-02 CO CONC2018/0011927A patent/CO2018011927A2/es unknown
- 2018-11-05 PH PH12018502327A patent/PH12018502327A1/en unknown
- 2018-12-03 ZA ZA2018/08161A patent/ZA201808161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU24576B1 (es) | 2022-02-04 |
| JP6997995B2 (ja) | 2022-02-04 |
| CN109476627A (zh) | 2019-03-15 |
| SG11201809843SA (en) | 2018-12-28 |
| EP3453704B1 (en) | 2021-06-16 |
| MX2018013422A (es) | 2019-08-16 |
| BR112018072579B1 (pt) | 2024-02-20 |
| CA3023073C (en) | 2022-08-30 |
| CN109476627B (zh) | 2021-06-15 |
| MX384967B (es) | 2025-03-14 |
| AU2017259749B2 (en) | 2021-08-19 |
| EA201892462A1 (ru) | 2019-07-31 |
| AU2017259749C1 (en) | 2021-12-02 |
| US20190133996A1 (en) | 2019-05-09 |
| EA037951B1 (ru) | 2021-06-11 |
| CL2018003114A1 (es) | 2019-06-14 |
| KR20210025138A (ko) | 2021-03-09 |
| ZA201808161B (en) | 2021-10-27 |
| EP3453704A1 (en) | 2019-03-13 |
| US10722491B2 (en) | 2020-07-28 |
| AR108370A1 (es) | 2018-08-15 |
| CO2018011927A2 (es) | 2019-02-08 |
| CU20160059A7 (es) | 2017-12-08 |
| KR102416478B1 (ko) | 2022-07-04 |
| WO2017190714A1 (es) | 2017-11-09 |
| JP2019516791A (ja) | 2019-06-20 |
| AU2017259749A1 (en) | 2018-12-20 |
| CA3023073A1 (en) | 2017-11-09 |
| ES2878579T3 (es) | 2021-11-19 |
| BR112018072579A2 (pt) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809843SA (en) | Phenolic compound and combination thereof with a benzodiazepin fused to 1,4-dihidropyridine for the treatment of central nervous and vascular systems affections | |
| SA517390509B1 (ar) | مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه | |
| AU2017264697A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| GEAP202014955A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| HK1212684A1 (zh) | 三環喹啉和喹喔啉衍生物 | |
| PH12017501570A1 (en) | Bicyclic ketone sulfonamide compounds | |
| WO2011041989A3 (es) | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular | |
| MX2015014947A (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| WO2017027810A3 (en) | Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| IL273943A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| MX368956B (es) | Derivados de 4-azaindol. | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| GB201610056D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| GB201610055D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| UA120083C2 (uk) | АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ | |
| NZ760781A (en) | Process for the preparation of standardized composition of arjunoglucoside from the bark of terminalia arjuna | |
| EA033297B1 (ru) | Терапевтические и питательные композиции для функциональных нарушений работы пищеварительной системы | |
| CU20160142A7 (es) | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4 dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease | |
| MY199288A (en) | Benzodiazepine derivative with activity on the central nervous and vascular systems | |
| CL2010001557A1 (es) | Compuestos derivados de bifenil sustituidos, inhibidores de fosfodiesterasa 10; composicion farmaceutica que los comprende a uno de los compuestos; y uso de la composicion en la preparacion de medicamentos para tratar desordenes neurologicos, neurodegenerativos y siquiatricos. |